TABLE 5.
Double-blind, n (%) | Mean maximum severity | Open label, n (%) | Mean maximum severity | |
---|---|---|---|---|
Constipation | 17 (32.1) | 1.3 | 19 (35.9) | 1.4 |
Nausea | 23 (43.4) | 1.7 | 8 (15.1) | 1.5 |
Dyspepsia | 1 (1.9) | 2.0 | 5 (9.4) | 2.0 |
Somnolence | 22 (41.5) | 1.5 | 5 (9.4) | 1.4 |
Anorexia | 5 (9.4) | 1.0 | 4 (7.5) | 1.5 |
Dizziness | 4 (7.5) | 1.5 | 4 (7.5) | 1.0 |
Pain | 4 (7.5) | 1.5 | 4 (7.5) | 1.8 |
Vasodilatation | 4 (7.5) | 1.8 | 4 (7.5) | 2.0 |
Urinary tract infection | 0 (0) | 0 | 4 (7.5) | 1.5 |
Vomiting | 3 (5.7) | 2.0 | 3 (5.7) | 1.7 |
Dry mouth | 9 (17.0) | 1.0 | 3 (5.7) | 1.0 |
Insomnia | 0 (0) | 0 | 3 (5.7) | 1.7 |
Hypertension | 1 (1.9) | 1.0 | 3 (5.7) | 1.3 |
Accidental injury | 1 (1.9) | 2.0 | 3 (5.7) | 1.7 |
Based on 53 patients exposed to open label controlled-release tramadol treatment.